Initial Results of a Study, in Collaboration With the UConn School of Medicine, Highlight the Potential of Ikonisys’ Cell-based Diagnostic Platform in Immuno-oncology
06 September 2021 - 05:45PM
Business Wire
- New demonstration of Ikonisys technology’s potential in
immuno-oncology through its ability to detect rare cells in general
and circulating tumor cells in particular
- Identification of 80 extremely rare antigen-specific CD8
T-Cells, in a background of over a million blood cells, through
high-speed scanning with the Ikoniscope20 platform
- Antigen-specific T cells which play a central role in
immunity to cancers and infectious agents through their capacity to
kill malignant cells upon recognition by T-cell receptor
Regulatory News:
Ikonisys SA (Code ISIN: FR00140048X2 / Mnémonique: ALIKO)
(Paris:ALIKO), a company specializing in the early and
accurate detection of cancers with a unique fully-automated
solution for medical analysis labs, announced the initial results
of a study to demonstrate the capability of the Ikoniscope20 rare
cell detection platform to enumerate specific populations of CD8 T
cells. Such antigen-specific CD8 T cells are extremely rare, and
are a perfect proof of demonstration of the ability to detect rare
cells in general, and circulating tumor cells in particular.
Antigen-specific T cells play a central role in immunity to cancers
and infectious agents (such as viruses), through their capacity to
kill malignant cells upon recognition by T-cell receptor of
specific antigenic peptides presented on the surface of target
cells. In this study, the two teams were able to identify about 80
antigen-specific T cells in a background of over a million blood
cells by high-speed scanning for the presence of cells positive for
fluorescently labelled MHC I-peptide complexes that bind to a T
cell antigen-receptor. The study was carried out in collaboration
with the Carole and Ray Neag Comprehensive Cancer Center of the
University of Connecticut (UConn) School of Medicine.
Prof. Pramod K. Srivastava, Director of the Carole and Ray
Neag Comprehensive Cancer Center (who also serves on the Board
of ALIKO), commented, “Detection and enumeration of cancer
antigen-specific T cells in a reliable and reproducible manner is
always challenging. These early results shall serve as a foundation
of the use of this technology in monitoring immune responses to
cancers in pre-clinical as well as clinical studies.”
Dr. Michael Kilpatrick, Chief Scientific Officer of
Ikonisys, added, “We are honored to be working with a leading
medical center to demonstrate the potential of the Ikonisys
platform in the detection and quantification of specific
populations of clinically relevant cells in immuno-oncology. The
study further validates the value of the Ikonisys platform for the
detection and analysis of specific populations of rare cells
present in complex specimens, an approach likely to have particular
value in the current era of personalized and predictive
medicine.”
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare and
very rare cells. Ikonisys has received FDA clearance for several
automated diagnostic applications, which are also marketed in
Europe under CE certification. Through its breakthrough
fluorescence microscopy platform, the company continues to develop
a stream of new tests, including liquid biopsy tests based on
Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com
Disclaimer
This press release contains forward-looking statements about the
Company's prospects and development. These statements are sometimes
identified by the use of the future tense, the conditional tense
and forward-looking words such as "believe", "aim to", "expect",
"intend", "estimate", "believe", "should", "could", "would" or
"will" or, where appropriate, the negative of these terms or any
other similar variants or expressions. This information is not
historical data and should not be construed as a guarantee that the
facts and data set forth will occur. This information is based on
data, assumptions and estimates considered reasonable by the
Company. It is subject to change or modification due to
uncertainties relating to the economic, financial, competitive and
regulatory environment. This information contains data relating to
the Company's intentions, estimates and objectives concerning, in
particular, the market, strategy, growth, results, financial
situation and cash flow of the Company. The forward-looking
information contained in this press release is made only as of the
date of this press release. The Company does not undertake to
update any forward-looking information contained in this press
release, except as required by applicable law or regulation. The
Company operates in a competitive and rapidly changing environment
and therefore cannot anticipate all of the risks, uncertainties or
other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any
one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information,
it being recalled that none of this forward-looking information
constitutes a guarantee of actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210906005230/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Olivier Bricaud / Louis-Victor Delouvrier Investor
Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Ikonisys (EU:ALIKO)
Historical Stock Chart
Von Mär 2023 bis Mär 2024